Veru (VERU)
(Delayed Data from NSDQ)
$0.77 USD
+0.02 (2.11%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.76 -0.01 (-1.29%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.77 USD
+0.02 (2.11%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $0.76 -0.01 (-1.29%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum D VGM
Zacks News
Asensus Surgical (ASXC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 25.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Veru Inc. (VERU): Can Its 39.5% Jump Turn into More Strength?
by Zacks Equity Research
Veru Inc. (VERU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -55.56% and 42.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Akerna Corp. (KERN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akerna Corp. (KERN) delivered earnings and revenue surprises of -16.67% and 13.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Lags Q2 Earnings Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -2.27% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Q2 Earnings Top Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 4.35% and 1.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Veru Inc. (VERU) closed at $12.10, marking a -0.9% move from the previous day.
Biotech Stock Roundup: ICPT's Study Data, NVAX Vaccine Gets EUA, VERU Up on Data
by Zacks Equity Research
Regulatory and other updates from Intercept (ICPT) and VERU are a few key highlights from the biotech sector during the past week.
Veru Inc. (VERU) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Veru Inc. (VERU) closed at $15, marking a -1.96% move from the previous day.
VERU's Shares Jump on Successful COVID-19 Study Results
by Zacks Equity Research
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Veru Inc. (VERU) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Veru Inc. (VERU) closed the most recent trading day at $11.30, moving -1.31% from the previous trading session.
Veru Inc. (VERU) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Veru Inc. (VERU) closed at $13.54 in the latest trading session, marking a +1.12% move from the prior day.
Meridian Bioscience (VIVO) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -12.50% and 14.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 26.87% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Stock Moves -1.8%: What You Should Know
by Zacks Equity Research
In the latest trading session, Veru Inc. (VERU) closed at $9.25, marking a -1.8% move from the previous day.
Earnings Preview: Veru Inc. (VERU) Q2 Earnings Expected to Decline
by Zacks Equity Research
Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Could Help Veru Inc. (VERU) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Veru Inc. (VERU) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Can Veru Inc. (VERU) Climb 344% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 343.6% upside potential for Veru Inc. (VERU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Earnings Preview: Veru Inc. (VERU) Q1 Earnings Expected to Decline
by Zacks Equity Research
Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug
by Zacks Equity Research
The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.
OrganiGram (OGI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.44%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of 37.50% and 14.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?